News Articles
Latest articles, insights, and updates from the blog.
Need help or want to reach readers?
Have a correction, provider question, or advertising inquiry? Reach the editorial team.
MedShadow Foundation Shares Key Ketamine Depression Facts
MedShadow Foundation releases important facts about ketamine as an antidepressant. Learn what patients should know before considering treatment.
Local TV News Highlights IV Ketamine Treatment Hope
FOX 4 Kansas City covers IV ketamine therapy as a new healing path, signaling growing mainstream acceptance of ketamine treatments.
GH Research Reports Phase 2 Results for Depression Treatment
GH Research reports Phase 2 results for GH001 in postpartum and treatment-resistant depression. Analysis of implications for ketamine patients.
Expert Highlights Key Patient Considerations for Ketamine
Dr. Benjamin Brody highlights critical patient considerations for ketamine therapy at ASCP meeting. Essential guidance for treatment evaluation.
2026 Psychedelic Policy Shifts: What Patients Should Know
A wave of state and federal psychedelic legislation in April 2026 could reshape the therapeutic landscape — here's what ketamine patients need to know.
Ketamine Therapy for Couples: What the Research Shows
Can couples do ketamine therapy together? What 2026 clinical research shows about ketamine for marriage, relationship repair, and joint dosing sessions.
FDA Clears Trial Pairing Ketamine Follow-Up Drug With TMS
The FDA cleared the MIND1 trial testing NRX-101 with robotic TMS for treatment-resistant depression and suicidality. What ketamine patients should know.
CBT After Esketamine Boosts Depression Outcomes in Trial
A new randomized trial finds that adding 16 weeks of CBT after esketamine significantly improves depression and suicidal ideation compared to esketamine alone.
FDA Clears NMDA Drug for Alzheimer's Agitation — What It Means for Ketamine Patients
The FDA approved Axsome's AXS-05 for Alzheimer's-related agitation. Here's what this NMDA antagonist approval means for ketamine therapy patients and the field.
FDA Fast-Tracks Psychedelics for Depression, PTSD, and AUD
The FDA is accelerating psychedelic drug development for treatment-resistant depression, PTSD, and AUD. What it means for patients exploring ketamine therapy.
AXS-05 Nears FDA Decision for Alzheimer's Agitation
AXS-05, an oral NMDA-targeting drug, nears FDA approval for Alzheimer's agitation. Here's what it means for the ketamine treatment landscape.
Side Effects & Dropout Rates: New Data on Ketamine for TRD
New clinical guidance on NMDA antagonist side effects and dropout rates offers practical insight for patients considering ketamine therapy for TRD.
Why Patients Quit NMDA Therapy—And What Providers Should Do
New clinical review urges faster dose optimization and earlier switching between NMDA therapies for treatment-resistant depression. Here's what it means for patients.